|
Efgartigimod alfa/hyaluronidase
Efgartigimod alfa/hyaluronidase, sold under the brand name Vyvgart Hytrulo, is a coformulation medication used for the treatment of generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy.[1] It contains efgartigimod alfa, a neonatal Fc receptor blocker, and hyaluronidase (human recombinant), an endoglycosidase.[1] Efgartigimod alfa/hyaluronidase may increase the risk of infection, including urinary tract infection and respiratory tract infections.[2] In clinical trials, hypersensitivity reactions, including rash, angioedema (swelling), dyspnea (shortness of breath), and urticaria (itchy welts) were observed in people treated with efgartigimod alfa.[2] The most common adverse reactions (≥ 10%) of people with myasthenia gravis treated with efgartigimod alfa were respiratory tract infections, headache, and urinary tract infection.[2] It was approved for medical use in the United States in June 2023.[3][4] Medical usesEfgartigimod alfa/hyaluronidase is indicated for the treatment of generalized myasthenia gravis in adults who are anti-acetylcholine receptor antibody positive.[1] In June 2024, the US Food and Drug Administration (FDA) expanded the indication for the combination to include the treatment of chronic inflammatory demyelinating polyneuropathy in adults.[2] HistoryThe effectiveness of the combination for the treatment of adults with chronic inflammatory demyelinating polyneuropathy was established in a two stage, multicenter study (Study 3; NCT04281472).[2] Study 3 included an open-label period (stage A) to identify people who had evidence of improvement with the use of Vyvgart Hytrulo, who then entered a randomized, double-blind, placebo-controlled, withdrawal period (stage B).[2] References
External links
Information related to Efgartigimod alfa/hyaluronidase |
||||||||||||||||||||||||||||
